Reimagining small molecule therapies for immune diseases
-
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models.
-
DeepCure collaborates with world-class researchers at the Leeds Institute of Rheumatic and Musculoskeletal Medicine.
-
DeepCure announces first development candidate, DC-9476, for multiple autoimmune diseases, including rheumatoid arthritis.
-
DeepCure's Inspired Chemistry™ platform for automated chemical synthesis makes top selling drug and 58 diverse analogs.